Company intelligence / Profile preview

Nuclein

Austin, Texas, United Statesnuclein.com ↗

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Nuclein has developed the DASH Rapid PCR System, a portable point-of-care diagnostic platform that delivers lab-quality PCR results in approximately 15 minutes with minimal hands-on time. The system is FDA-cleared and CLIA-waived for its multiplexed SARS-CoV‑2 & Flu A/B test. The company is expanding its menu to include additional infectious disease tests.

Therapeutic areas: Infectious Diseases
Modalities: DevicePCR-based diagnostics (Polymerase Chain Reaction)
Industry: Molecular Diagnostics

Partnerships

Trinity Investors / Trinity Private Equity Group (lead investor and board representation)

Beyond the preview

Go deeper on Nuclein.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuclein.

Explore the full profile